{"id":"group-hydroxychloroquine-and-apixaban","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding (apixaban-related)"},{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Retinopathy (hydroxychloroquine-related, long-term)"},{"rate":null,"effect":"Myalgia or arthralgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Hydroxychloroquine works by accumulating in lysosomes, reducing inflammatory cytokine production and modulating immune responses, making it useful in autoimmune and inflammatory conditions. Apixaban is a direct Factor Xa inhibitor that prevents thrombin generation and clot formation. Together, this combination may address both inflammatory/autoimmune pathology and associated thrombotic risk.","oneSentence":"This combination pairs hydroxychloroquine, an immunomodulator that reduces inflammation and autoimmune activity, with apixaban, an anticoagulant that inhibits Factor Xa to prevent thrombosis.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:14:33.500Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Likely autoimmune or inflammatory condition with thrombotic risk (specific indication not publicly detailed for this Phase 3 trial)"}]},"trialDetails":[{"nctId":"NCT05894954","phase":"PHASE3","title":"Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment","status":"COMPLETED","sponsor":"Alzheimer's Prevention and Reversal Project, Inc.","startDate":"2023-07-31","conditions":"Mild Cognitive Impairment, Dementia, Mild","enrollment":73},{"nctId":"NCT04788355","phase":"PHASE3","title":"Prevention of Complications (SARS-CoV-2): Clinical Study","status":"COMPLETED","sponsor":"Universidade do Vale do Sapucai","startDate":"2020-07-01","conditions":"Complication","enrollment":176}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Hydroxychloroquine, Apixaban and standard treatment"],"phase":"phase_3","status":"active","brandName":"Group Hydroxychloroquine and apixaban","genericName":"Group Hydroxychloroquine and apixaban","companyName":"Universidade do Vale do Sapucai","companyId":"universidade-do-vale-do-sapucai","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination pairs hydroxychloroquine, an immunomodulator that reduces inflammation and autoimmune activity, with apixaban, an anticoagulant that inhibits Factor Xa to prevent thrombosis. Used for Likely autoimmune or inflammatory condition with thrombotic risk (specific indication not publicly detailed for this Phase 3 trial).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}